Celularity, Inc. (CELU)
1.25
-0.08
(-6.02%)
USD |
NASDAQ |
Oct 16, 16:00
1.23
-0.02
(-1.60%)
After-Hours: 20:00
Celularity Research and Development Expense (Annual) : 9.222M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 9.222M |
| December 31, 2024 | 11.22M |
| December 31, 2023 | 23.33M |
| Date | Value |
|---|---|
| December 31, 2022 | 71.12M |
| December 31, 2021 | 81.73M |
| December 31, 2020 | 47.93M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Tenax Therapeutics, Inc. | 32.67M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 3.286M |
| Century Therapeutics, Inc. | 82.57M |
| Absci Corp. | 80.72M |